Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy.

Authors :: Guisado-Vasco P
González-Cortijo L
D'Errico G
Serrera-Alvarez A
Sotres-Fernandez G
García-Coca M
Fernández-Sousa JM
Luepke-Estefan XE
López-Martín JA
Jimeno JM
Source :: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Oct; Vol. 32 (10), pp. 1295-1297. Date of Electronic Publication: 2021 Jul 07.
Publication Year :: 2021
Abstract: Competing Interests: Disclosure JMF-S is President and Founder of PharmaMar, S.A. (Madrid, Spain). JJ holds stocks of Pangae Oncology, has a non-remunerated role in the Scientific Advisory Board and holds stocks of Phosplatin Therapeutics; and is a full-time employee of PharmaMar, S.A. (Madrid, Spain). JAL-M is employee and shareholder of PharmaMar, S.A (Madrid, Spain), and also a co-inventor of a patent for plitidepsin (WO2008135793A1). XELE is employee and shareholder of PharmaMar, S.A (Madrid, Spain). All other authors have declared no conflicts of interest.

Subjects :: Antineoplastic Agents therapeutic use
Humans
Depsipeptides therapeutic use
Neoplasms drug therapy
Peptides, Cyclic therapeutic use
COVID-19 Drug Treatment

Language :: English
ISSN :: 1569-8041
Volume :: 32
Issue :: 10
Database :: MEDLINE
Journal :: Annals of oncology : official journal of the European Society for Medical Oncology
Publication Type :: Report
Accession number :: 34242743
Full Text :: https://doi.org/10.1016/j.annonc.2021.07.003

Full Text Access

Tools